Pharmaceutical Anglo-Swedish drug major AstraZeneca (LSE: AZN) has launched what it says is its first-ever direct-to-patient program offering those with a valid prescription for its breast cancer drug Arimidex (anastrozole), which has lost patent exclusivity, the opportunity to have the brand Arimidex delivered directly to their home by Express Scripts, a specialty pharmacy services provider in the USA, for $40 per month, including shipping. 16 February 2012